A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

This study is testing sacituzumab govitecan, a targeted antibody-drug treatment, for people whose cervical cancer has come back or has not responded to prior treatment. The drug delivers chemotherapy directly to cancer cells using a homing molecule that targets a protein called TROP-2. **You may be eligible if...** - You have cervical cancer that has returned or is persisting after at least one prior chemotherapy regimen - Your cancer has been confirmed by imaging (CT or MRI) - You have a tumor tissue sample available for testing - You are in adequate health to tolerate treatment **You may NOT be eligible if...** - You have not had any prior chemotherapy (note: weekly cisplatin given alongside radiation does not count) - You have uncontrolled infections or serious medical conditions - You have received prior treatment with sacituzumab govitecan or similar agents - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.